1. Home
  2. WLYB vs NNNN Comparison

WLYB vs NNNN Comparison

Compare WLYB & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WLYB
  • NNNN
  • Stock Information
  • Founded
  • WLYB 1807
  • NNNN 2021
  • Country
  • WLYB United States
  • NNNN Germany
  • Employees
  • WLYB N/A
  • NNNN N/A
  • Industry
  • WLYB Books
  • NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • WLYB Consumer Discretionary
  • NNNN Health Care
  • Exchange
  • WLYB Nasdaq
  • NNNN Nasdaq
  • Market Cap
  • WLYB 2.1B
  • NNNN 2.2B
  • IPO Year
  • WLYB N/A
  • NNNN 2025
  • Fundamental
  • Price
  • WLYB $37.05
  • NNNN $23.34
  • Analyst Decision
  • WLYB
  • NNNN
  • Analyst Count
  • WLYB 0
  • NNNN 0
  • Target Price
  • WLYB N/A
  • NNNN N/A
  • AVG Volume (30 Days)
  • WLYB 583.0
  • NNNN 76.8K
  • Earning Date
  • WLYB 12-04-2025
  • NNNN 11-11-2025
  • Dividend Yield
  • WLYB 3.81%
  • NNNN N/A
  • EPS Growth
  • WLYB N/A
  • NNNN N/A
  • EPS
  • WLYB 1.78
  • NNNN 0.06
  • Revenue
  • WLYB $1,670,600,000.00
  • NNNN $8,185,146.00
  • Revenue This Year
  • WLYB $0.86
  • NNNN N/A
  • Revenue Next Year
  • WLYB $2.66
  • NNNN N/A
  • P/E Ratio
  • WLYB $20.20
  • NNNN $426.55
  • Revenue Growth
  • WLYB N/A
  • NNNN 21.95
  • 52 Week Low
  • WLYB $36.20
  • NNNN $5.18
  • 52 Week High
  • WLYB $52.90
  • NNNN $55.65
  • Technical
  • Relative Strength Index (RSI)
  • WLYB 42.08
  • NNNN 34.85
  • Support Level
  • WLYB $37.05
  • NNNN $21.60
  • Resistance Level
  • WLYB $37.55
  • NNNN $30.65
  • Average True Range (ATR)
  • WLYB 0.58
  • NNNN 2.47
  • MACD
  • WLYB -0.01
  • NNNN -0.15
  • Stochastic Oscillator
  • WLYB 21.60
  • NNNN 18.71

About WLYB John Wiley & Sons Inc.

John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

Share on Social Networks: